These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27906780)

  • 1. Developing a dedicated comprehensive α-radionuclide therapy program: should this be the vision of the atomic energy programs in the next decade?
    Basu S; Banerjee S
    Nucl Med Commun; 2017 Feb; 38(2):103-105. PubMed ID: 27906780
    [No Abstract]   [Full Text] [Related]  

  • 2. Envisaging an alpha therapy programme in the atomic energy establishments: the priorities and the nuances.
    Basu S; Banerjee S
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1244-1246. PubMed ID: 28364163
    [No Abstract]   [Full Text] [Related]  

  • 3. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
    Radchenko V; Schaffer P; Knapp FFR
    Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
    [No Abstract]   [Full Text] [Related]  

  • 4. Nuclear energy and medicine: the Canadian connection.
    Gray C
    Can Med Assoc J; 1984 Feb; 130(3):299-304. PubMed ID: 6692215
    [No Abstract]   [Full Text] [Related]  

  • 5. [Trends in the use of radiopharamaceuticals in the Federal Republic of Germany].
    Fogel' Iu
    Med Radiol (Mosk); 1982 Aug; 27(8):69-71. PubMed ID: 7132606
    [No Abstract]   [Full Text] [Related]  

  • 6. Nuclear medicine. Scrambling to close the isotope gap.
    Service RF
    Science; 2011 Jan; 331(6015):277-9. PubMed ID: 21252324
    [No Abstract]   [Full Text] [Related]  

  • 7. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiolanthanides in nuclear medicine.
    Rösch F; Forssell-Aronsson E
    Met Ions Biol Syst; 2004; 42():77-108. PubMed ID: 15206100
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted α therapy for cancer: where we are today and where we are heading.
    Melville G
    Future Oncol; 2015 Nov; 11(22):3065-7. PubMed ID: 26436906
    [No Abstract]   [Full Text] [Related]  

  • 11. Short- and long-term responses to molybdenum-99 shortages in nuclear medicine.
    Ballinger JR
    Br J Radiol; 2010 Nov; 83(995):899-901. PubMed ID: 20965898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy Department proposes two isotope initiatives.
    Rojas-Burke J
    J Nucl Med; 1993 Jun; 34(6):47N-48N. PubMed ID: 8509849
    [No Abstract]   [Full Text] [Related]  

  • 13. TESLA Accelerator Installation at Vinca. Production of radioisotopes for nuclear-medical applications.
    Vucina J; Memedović T; Vuksanović L
    Med Pregl; 1993; 46 Suppl 1():103-4. PubMed ID: 8569591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report hints at restructuring of DOE isotope program.
    Rojas-Burke J
    J Nucl Med; 1993 Jun; 34(6):49N, 54N. PubMed ID: 8509850
    [No Abstract]   [Full Text] [Related]  

  • 15. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
    Allen BJ
    Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
    [No Abstract]   [Full Text] [Related]  

  • 16. A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, "Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry".
    Padhy AK; Dondi M
    Semin Nucl Med; 2008 Mar; 38(2):S5-12. PubMed ID: 18243843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the scientific highlights at the European Association of Nuclear Medicine Congress, Vienna 1991.
    Fueger GF
    Eur J Nucl Med; 1992; 19(4):287-305. PubMed ID: 1597246
    [No Abstract]   [Full Text] [Related]  

  • 18. [Future views in nuclear medicine].
    Liewendahl K
    Duodecim; 1993; 109(11):970-7. PubMed ID: 8062669
    [No Abstract]   [Full Text] [Related]  

  • 19. Energy Department molybdenum plan faltering.
    J Nucl Med; 1993 Apr; 34(4):20N. PubMed ID: 8455070
    [No Abstract]   [Full Text] [Related]  

  • 20. The Energy Department's modest proposal.
    Rojas-Burke J
    J Nucl Med; 1993 Apr; 34(4):13N-14N, 17N-18N. PubMed ID: 8455069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.